Go to Client Portal

MedTech Chats: MEGA BIOPHARMA Partners with NAMSA to De-Risk Disruptive Dental Technology

In NAMSA’s first edition of “MedTech Chats,” we sit down with MEGA BIOPHARMA’s Bone Division Director and Dental Surgeon, Dr. Laurent Helewa.

What follows is a discussion regarding the French company’s disruptive product, Bionacre®, a natural biomaterial extracted from nacre that has yielded scientifically proven results in the domains of bone and skin repair. We discover how a long-forgotten technology, Mother-of-Pearl, is now providing significant advantages for bone/tissue regeneration and positive impacts to the industries of Dental Surgery, Orthopedics, Dermo-Cosmetics, Dermatology and Veterinary Care.

Additionally, Dr. Laurent highlights how NAMSA’s APEX Program™ is serving a key role in helping MEGA BIOPHARMA effectively communicate with stakeholders, de-risk the program and set the stage for successful U.S. Food and Drug Administration (FDA) 510(k) regulatory submission and approval.

Access this MedTech Chat by clicking the Download PDF button on the left-hand panel.